Spun out of research from the University of California Irvine, Proveri Inc. had developed a new strategy for producing improved prostate cancer diagnosis and prognosis of disease outcome. The company's approach utilizes unique properties of the Prostate Tumor Microenvironment, which is a rich source of diagnostic and prognostic biomarkers and is nearly free of genetic heterogeneity compared to tumor epithelial tissue. Because the tumor microenvironment is genetically stable, the biomarkers that are derived have a higher chance of being applicable to a broader patient population. The company's clinical assays based on stroma-derived biomarkers have demonstrated 97% overall accuracy of tumor diagnosis and 87% accuracy of prognostics for detecting aggressive cancer. Though site remains online no indicationof upadtes sinec 2103. Assume the firm is no longer operational/
